SMC approves funding for four new medicines on the NHS
SMC approves funding for four new medicines on the NHS 9th February 2021 In its February 2021 meeting, the Scottish Medicines Consortium (SMC) has accepted four new medicines for use by the NHS in Scotland. Bristol Myers Squibb’s (BMS) multiple sclerosis (MS) oral therapy Zeposia (ozanimod) has been accepted for the treatment of relapsing-remitting MS (RRMS). Zeposia is used in RRMS patients with active disease, where patients have relapses or signs of active inflammation on scans. Also approved for use by NHS Scotland was AbbVie’s JAK inhibitor Rinvoq, which has been accepted for the tre...